

# Moving with the times<sup>™</sup>

A new generation joint health solution

Joris Dewit **Business Development Director** CHI, Lonza

## Agenda

# **Active Aging Market & Consumer Demand**

 Consumer Insights & Benefits

### **UC-II**® **Product Overview**

- What is UC-II<sup>®</sup>?
- Science Clinical & Animal Research
- Mechanism of Action
- UC-II Ready to Market Product Range
- Summary and Value Proposition

### Q&A




# Moving with the times<sup>™</sup>

A wide range of consumers with different needs/ concerns to address




initiative: Hidden Impact of Musculoskeletal disorders,2014

# Active Silver Ager dosage form preference



Source NMI 2019 ITALY

### What is UC-II®



- Undenatured (native) type II collagen derived from chicken sternum cartilage
- Trademarked, patented, clinically studied ingredient for joint health
- Manufactured in USA under food GMP conditions
- Small dose (40 mg/once per day)
- Unique mechanism of action (oral tolerance)
- Backed by preclinical and clinical science


Making the difference with UC-II® undenatured type II collagen

### UC-II® Undenatured type II collagen


- No heat
- No enzyme
- Gentle processing

#### **Retained Structure**

- Intact polypeptides
- Active epitopes



Gelatin	Hydrolyzed collagen
<ul><li>Partial hydrolysis (heat)</li><li>Harsh processing</li></ul>	<ul><li>Complete hydrolysis (heat + enzyme)</li><li>Harsher processing</li></ul>
Disrupted Structure	Disrupted Structure
<ul><li>Mixture of peptides and polypeptides</li><li>No active epitopes</li></ul>	<ul><li>Amino acids &amp; small peptides</li><li>No active epitopes</li></ul>
Mans.	



\* Lugo et al., J Int Soc Sports Nutr. 2013;10:48 \*\* Lugo JP, et al. Nutr J. 2016;15:14. \*\*\* Bagi et al., Osteoarthritis Cartilage 2017; 25:2080-90

# UC-II® healthy subjects study


Randomized, double-blind, placebo-controlled study



Groups	Group 1: UC-II <sup>®</sup> Brand, 40 mg Group 2: Placebo	
Subjects	N=55	
Duration	120 Days	
Primary Endpoint	Improvement in knee function	
Secondary Endpoints	Time to onset of knee joint pain on Stepmill Time to offset of knee joint pain after stepping off the Stepmill	
Time Points Measured	0, 7, 30, 60, 90 and 120 days	
Average Age of Subjects	46 years	

# UC-II® healthy subjects study

Randomized, double-blind, placebo-controlled study





UC-II® undenatured type II collagen significantly increase average knee extension compared to placebo



UC-II® undenatured type II collagen appears to be alleviating joint discomfort in healthy subject



Participants in UC-II group exercised longer before experiencing joint discomfort and recovered faster from joint discomfort.



17-week supplementation with UC-II® undenatured type II collagen was well tolerated

# UC-II® Osteo Arthritis Study

Randomized, double-blind, placebo-controlled study

Study Design				
3 Groups	Placebo GC (1500 mg G + 1200 mg C) UC-II <sup>®</sup> Brand (40 mg)			
Subjects	N = 186			
Primary Endpoint	Change in Total WOMAC at Day 180 vs PBO & GC			
Secondary Endpoints	Mean VAS, LFI and WOMAC Subscales at Day 180 vs PBO & GC			
Visits	Days 0, 7, 30, 60, 90, 120, 150 & 180			
Population	Osteoarthritic subjects (Moderate to severe)			
# Centers	13 clinics participated in study			


Western Ontario and McMaster
Universities Osteoarthritis Index
(WOMAC) — A clinically validated
questionnaire used to assess arthritis
symptoms in three domains (subscales):
physical function, stiffness and knee pain.

## UC-II® Osteo Arthritis study


Randomized, double-blind, placebo-controlled study

#### **Total WOMAC Score Reduction**

- UC-II® brand achieved statistical significance versus placebo and GC
- GC failed to achieve significance versus placebo









UC-II® achieved statistical signifiance versus GC




GC did not achieve statistical signifiance versus placebo



UC-II<sup>®</sup> is safe and effective

# UC-II® Unique mode of action

### Lonza



## UC-II® ready-to-market joint health formulation

### Science Backed UC-II<sup>®</sup> ingredient:

 May trigger natural rebuild of cartilage in your joints during the joint repair cycle and daily activities, exercise or normal stress

#### • Convenience product:

1 small clean label capsule a day

#### Market proof Formulation:

- Robust and tested formulation
- Includes Vit C, Vit D3, Manganese, Copper for health claims on joint health





## UC-II® Consumer convenience

Just one tiny easy to swallow capsule daily

### "One tiny pill per day"



• 75% OF THE CONSUMERS CONSIDER EASY TO SWALLOW AS IMPORTANT IN THEIR BUYING DECISION OF FOOD SUPPLEMENTS



• UC-II® UNDENATURED TYPE II COLLAGEN
SUPPORTS JOINT HEALTH IN ONE, 40 MG DOSE



vs 3 GLUCK

TABLETS CONTAINING
GLUCOSAMINE AND CHONDROITIN

40mg UC-II® significantly outperforms 1500mg Glucosamine and 1200mg Chondroitine

(Lugo et al. Nutr J. 2016:15:14)



# UC-II<sup>®</sup> Moving with the times<sup>™</sup> portfolio

### Complete range of ready to market products


- UC-II® Portfolio addresses the needs of different age groupes and their specific concerns to keep their mobility
- Convenient backed by science UC-II formulations that support joint health claims
- Specific UC-II® combination products for consumers looking into food supplement products addressing joint inflammation concerns.
- Innovative UC-II® combination products that address synergetic concerns eg joint bone health.

Vit C, Vit D, Mn, Cu	Anti-oxidants		Science Backed, size 2 formulation	
Curcumin, Boswelia.	Anti- inflammatory	TICH!	DUOCAP high bioavailable tumerid	
Omega3, Vit D	Anti- initaminatory	UCII	SOFTGEL Omega 3	
Vit K2	Directs Ca towards the bones		Synergetic joint-bone health formulation	6

### UC-II® Curcumin Active

DUOCAP® Capsule in capsule high performance ingredients combination


- Science Backed ingredients:
  - May trigger natural rebuild of cartilage in your joints during the joint repair cycle and daily activities, exercise or normal stress
  - Contains 40 mg UC-II<sup>®</sup> undenatured type II collagen for single daily dose
  - Contains NOVASOL® liquid formulation of clinically proven high bioavailable Curcumin
  - 1 single daily dose easy to swallow capsule.



## UC-II® Vit K2


### Holistic approach for the Musculoskeletal system

- Synergetic science backed ingredients:
  - UC-II® triggers the chondrocytes to rebuild cartilage
  - Vit K2 ensures activation of bone building Osteocalcin
- Ready to market formulation:
  - 1 single capsule dose a day contains 40 mg of UC-II<sup>®</sup>
  - VIT K2, Vit C and Vit D3 for joint/bone health claims
  - K2VITAL® 100% pure and stable Vitamin K2
- Consumer convenience:
  - Small size 2 easy to swallow Licaps<sup>®</sup> liquid filled capsule.



# End-to-end partnership

Formulation development, dosage form expertise, go to market services



# Take Away's

Backed by science ingredient shown in multiple published studies to be effective

Found to im, mobility and fix.

2016 2017


Significantly ' and chose' place'

Significantly more effective than Glucosamine plus Chondroitin.

Changing consumer landscape requires new solutions to address mobility concerns







Unique mode of action (Oral tolerance)

UC-II® 40mg daily dose can replace bulkier, less efficacious ingredients with a smaller serving size





INNER CAPSULE
CONTAINS 40MG UC-II DAILY DOSE
OUTER CAPSULE
'NS HIGH BIOAVAILABLE CUP'

Vcaps® Plus, DUOCAP™ and Licaps® innovative dosage forms can be used to create synergetic formulations.

### Contact us

solutions.emea@lonza.com

www.capsugel.com

This document is an overview for professionals and must not be distributed as such to consumers. Recipient must ensure that final communications to the consumer on food and food supplements products comply with the applicable health claims regulations in the regions / countries where the final products are marketed. Review and follow all product safety instructions. The statements made in these materials have not been evaluated by the U.S. Food and Drug Administration or any other regulatory authority. Lonza's products are not intended for use to diagnose, treat, cure or prevent any disease. All information in this presentation corresponds to Lonza's knowledge on the subject at the date of publication and on the information published by the ingredient manufacturers. However Lonza makes no warranty as to its accuracy or completeness and Lonza assumes no obligation to update it. All information in this presentation is intended for use by recipients experienced and knowledgeable in the field, who are capable of and responsible for independently determining the suitability and to ensure their compliance with applicable law. Proper use of this information is the sole responsibility of the recipient. This information may not be applicable, complete or suitable for the recipient's finished product or application; therefore republication of this information or related statements is prohibited. Information provided in this presentation by Lonza is not intended and should not be construed as a license to operate under or a recommendation to infringe any patent or other intellectual property right. All trademarks belong to Lonza or its affiliates or to their respective third parties and are used here only for informational purposes. Copyrighted material has been produced with permissions or under license, all other materials belong to Lonza. © 2020 Lonza.